Citations

Showing 10 of 108104 citations.

Is It Actionable? An Evaluation of the Rapid PCR-Based Blood Culture Identification Panel on the Management of Gram-Positive and Gram-Negative Blood Stream Infections
Kasule, Sabirah N, Rice, Felicia, Mi, Lanyu , Chan, Lynn, Seville, Maria Teresa , Tseng, Andrew S. , Seville, Maria T., Grys, Thomas E.

Mayo Clinic

Open Forum Infectious Diseases | December 19, 2018 | Volume: 5 | Issue: 12 | Pages: No page available

10.1093/ofid/ofy308 | PMID 30555850 Get It

Abstract Background There is growing interest in the use of rapid blood culture identification (BCID) in antimicrobial stewardship programs (ASPs). Although many studies have looked at its clinical and economic utility, its comparative utility in gram-positive and gram-negative blood stream infections (BSIs) has not been as well characterized. Methods The study was a quasi-experimental retrospective study at the Mayo Clinic in Phoenix, Arizona. All adult patients with positive blood cultures before BCID implementation (June 2015 to December 2015) and after BCID implementation (June 2016 to December 2016) were included. The outcomes of interest included time to first appropriate antibiotic escalation, time to first appropriate antibiotic de-escalation, time to organism identification, length of stay, infectious diseases consultation, discharge disposition, and in-hospital mortality. Results In total, 203 patients were included in this study. There was a significant difference in the time to organism identification between the pre- and post-BCID cohorts (27.1 hours vs 3.3 hours, P < .0001). BCID did not significantly reduce the time to first appropriate antimicrobial escalation or de-escalation for either gram-positive BSIs (GP-BSIs) or gram-negative BSIs (GN-BSIs). Providers were more likely to escalate antimicrobial therapy in GP-BSIs after gram stain and more likely to de-escalate therapy in GN-BSIs after susceptibilities. Although there were no significant differences in changes in antimicrobial therapy for organism identification by BCID vs traditional methods, more than one-quarter of providers (28.1%) made changes after organism identification. There were no differences in hospital length of stay or in-hospital mortality comparing pre- vs post-BCID. Conclusions Although BCID significantly reduced the time to identification for both GP-BSIs and GN-BSIs, BCID did not reduce the time to first appropriate antimicrobial escalation and de-escalation.
Minimally Invasive and Regenerative Therapeutics
Ahadian, Samad , Darabi, Mohammad Ali , Tahchi, Mario El , Lee, Junmin , Suthiwanich, Kasinan , Sheikhi, Amir , Dokmeci, Mehmet R. , Öklü, Rahmi , Khademhosseini, Ali , Khademhosseini, Ali , Khademhosseini, Ali , Oklu, Rahmi , Khademhosseini, Ali , Dokmeci, Mehmet Remzi , Ashammakhi, Nureddin A. , Suthiwanich, Kasinan

Mayo Clinic

Advanced Materials | December 19, 2018 | Volume: 31 | Issue: 1 | Pages: No page available

10.1002/adma.201804041 | PMID 30565732 Get It

Abstract Advances in biomaterial synthesis and fabrication, stem cell biology, bioimaging, microsurgery procedures, and microscale technologies have made minimally invasive therapeutics a viable tool in regenerative medicine. Therapeutics, herein defined as cells, biomaterials, biomolecules, and their combinations, can be delivered in a minimally invasive way to regenerate different tissues in the body, such as bone, cartilage, pancreas, cardiac, skeletal muscle, liver, skin, and neural tissues. Sophisticated methods of tracking, sensing, and stimulation of therapeutics in vivo using nano‐biomaterials and soft bioelectronic devices provide great opportunities to further develop minimally invasive and regenerative therapeutics (MIRET). In general, minimally invasive delivery methods offer high yield with low risk of complications and reduced costs compared to conventional delivery methods. Here, minimally invasive approaches for delivering regenerative therapeutics into the body are reviewed. The use of MIRET to treat different tissues and organs is described. Although some clinical trials have been performed using MIRET, it is hoped that such therapeutics find wider applications to treat patients. Finally, some future perspective and challenges for this emerging field are highlighted.
Adaptation, Dissemination, and evaluation of A Cancer Palliative Care Curriculum for the Indian Health System
Arenella, Cheryl , Finke, Bruce, Domer, Timothy, Kaur, Judith S. , Merriman, Melanie P., Ousley, Anita

Mayo Clinic

Journal of Palliative Care | December 19, 2018 | Volume: 26 | Issue: 1 | Pages: 15-21

10.1177/082585971002600104 Get It

In 2006, the Indian Health Service (IHS) and the National Cancer Institute (NCI) collaborated to develop an interdisciplinary palliative training program for health professionals in the Indian health system. Their goal was to improve clinician knowledge and skills in palliative care, to train future trainers, and to increase access to palliative care for American Indians and Alaska Natives. The combined program of participant self-study utilizing a multimedia CD-ROM and train-the-trainer seminars followed the curriculum entitled Education in Palliative and End-of-Life Care for Oncology (EPEC ™ -O) with American Indian and Alaska Native Cultural Considerations. Three seminars trained 89 interdisciplinary health providers from throughout the Indian health system. Evaluations demonstrated increased clinician self-reported knowledge and confidence to train and high satisfaction with training. Forty-two of 67 participants completed an anonymous post-conference Web questionnaire. Nearly half had con ducted or definitively planned palliative education sessions, and 57 percent started new palliative services at their practice sites.
Surgical Dissection of a Perimedullary Fistula of Conus Medullaris With Long-Term Follow-Up: 2-Dimensional Operative Video
Sorenson, Thomas J. , Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | December 19, 2018 | Volume: 17 | Issue: 2 | Pages: E59-E59

10.1093/ons/opy346 | PMID 30566617 Get It

Abstract Perimedullary fistulae of the spinal cord are rare vascular lesions that can present with different clinical patterns: hemorrhage, progressive myelopathy due to arterial steal and/or venous congestion, or symptoms due to compression of neural structures by engorged vessels. Treatment consists of surgical excision, endovascular embolization, or a combination of the two. If complete obliteration of the nidus exposes the patient to undue risk of permanent neurological deficits, incomplete obliteration with reduction of the vascular supply is a reasonable compromise to improve clinical symptomatology. Partial devascularization may also alter the natural history by decreasing the risk of further growth and bleeding. In this video we illustrate the case of a patient with a perimedullary fistula of the conus treated with surgical disconnection of the main fistulous component. Partial devascularization resulted in resolution of MRI signal changes and symptoms with documented good clinical and radiological outcome and progressive regression of the residual nidus over six years of follow-up.
The Effects of Resection Technique on Implant Migration in Single Radius Posterior-Stabilized Total Knee Replacement
Teeter, Matthew G. , Perry, Kevin I. , Yuan, Xunhua , Howard, James L. , Perry, Kevin, Lanting, Brent A.

Mayo Clinic

The Journal of Knee Surgery | December 19, 2018 | Volume: 33 | Issue: 01 | Pages: 078-083

10.1055/s-0038-1676462 | PMID 30562833 Get It

AbstractThe purpose of the present study was to measure the effects of gap balancing and resection techniques on migration of a single total knee replacement implant design. A total of 23 patients (24 knees) were recruited on referral to either a surgeon performing gap balancing or a surgeon performing measured resection and followed prospectively. All patients received a fixed bearing, posterior stabilized total knee replacement implant of a single radius femoral component design with cement fixation, and all aspects of care outside of resection technique were identical. Patients underwent radiostereometric analysis (RSA) at 2 weeks (baseline), 6 weeks, 3 months, 6 months, 1 year, and 2 years. Migration of the tibial and femoral components was compared between groups. Tibial component migration was greater at 2 years in the gap balancing group (mean difference = 0.336 mm, p = 0.036), but there was no difference at 1 year. One measured resection and three gap balancing tibial components demonstrated continuous migration > 0.2 mm between years 1 and 2. There was no difference in femoral component migration. Small differences in tibial component migration were found between the gap balancing and measured resection techniques. However, comparing the migration to established predictive thresholds for long-term loosening risk, implants performed with both techniques were found to have equally low revision risk.
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Rampal, Raajit K. , Price, Leah , Berenzon, Dmitriy, Abboud, Camille N. , Kremyanskaya, Marina , Weinberg, Rona Singer , Salama, Mohamed E. , Menghrajani, Kamal , Najfeld, Vesna , Sandy, Lonette, Heaney, Mark , Levine, Ross L. , Dueck, Amylou C. , Goldberg, Judith D. , Dueck, A. C. , Price, Leah , Goldberg, Judith D , Najfeld, Vesna , Mascarenhas, John , Kosiorek, Heidi , Hexner, Elizabeth O. , Mesa, Ruben A. , Hoffman, Ronald

Mayo Clinic

Blood Advances | December 18, 2018 | Volume: 2 | Issue: 24 | Pages: 3572-3580

10.1182/bloodadvances.2018019661 | PMID 30563881 Get It

Abstract Myeloproliferative neoplasms (MPN), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to evolve into accelerated and blast-phase disease (MPN-AP/BP), carrying a dismal prognosis. Conventional antileukemia therapy has limited efficacy in this setting. Thus, MPN-AP/BP is an urgent unmet clinical need. Modest responses to hypomethylating agents and single-agent ruxolitinib have been reported. More recently, combination of ruxolitinib and decitabine has demonstrated synergistic in vitro activity in human and murine systems. These observations led us to conduct a phase 1 study to explore the safety of combined decitabine and dose-escalated ruxolitinib in patients with MPN-AP/BP. A total of 21 patients were accrued to this multicenter study. Ruxolitinib was administered at doses of 10, 15, 25, or 50 mg twice daily in combination with decitabine (20 mg/m2 per day for 5 days) in 28-day cycles. The maximum tolerated dose was not reached. The most common reasons for study discontinuation were toxicity/adverse events (37%) and disease progression (21%). Fourteen patients died during study treatment period or follow-up. The median overall survival for patients on study was 7.9 months (95% confidence interval, 4.1-not reached). Among evaluable patients, the overall response rate by protocol-defined criteria (complete remission with incomplete count recovery + partial remission) was 9/17 (53%) and by intention-to-treat analysis was 9/21 (42.9%). The combination of decitabine and ruxolitinib was generally well tolerated by patients with MPN-AP/BP and demonstrates potentially promising clinical activity. A phase 2 trial evaluating the efficacy of this combination regimen is ongoing within the Myeloproliferative Disorder Research Consortium.
1016: USEFULNESS OF POINT-OF-CARE ULTRASOUND FOR CHARACTERIZATION OF PRE-LIVER TRANSPLANT PLEURAL EFFUSION
Kwon, Minkyung , Prada, Gabriel , Marenco, Lina, Canabal, Juan, Keaveny, Andrew P. , Pai, Sher‐Lu , Díaz‐Gómez, José L.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 486-486

10.1097/01.ccm.0000551764.90373.73 Get It

1596: CEREBRAL MALARIA: AN ATOVAQUONE A DAY KEEPS THE DOCTOR AWAY
Kinsman, Kristiann, Myers, Melissa A , Park, John, Wijdicks, Eelco F. M.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 773-773

10.1097/01.ccm.0000552338.61360.bb Get It

1558: PREDICTORS OF DYSRHYTHMIAS WITH NOREPINEPHRINE USE IN SEPTIC SHOCK PATIENTS
Davidson, K. Erin, Jones, Gary M., Samarin, Michael, Kimmons, Lauren A. , Jones, G. Morgan

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 755-755

10.1097/01.ccm.0000552301.47899.e2 Get It